Next Generation Sequencing (NGS) Market
  • CHOOSE LICENCE TYPE
Consulting Services
    How will you benefit from our consulting services ?

Global Next Generation Sequencing (NGS) Market Size, Share, Trends and Forecasts 2031

Last Updated:  Jul 04, 2025 | Study Period: 2025-2031

Key Findings

  • Next Generation Sequencing (NGS) technologies enable high-throughput and parallel sequencing of millions of DNA and RNA fragments, revolutionizing genomics, transcriptomics, and precision medicine.
  • The widespread adoption of NGS in clinical diagnostics, oncology, infectious disease surveillance, and pharmacogenomics is driving rapid market growth.
  • Advancements in sequencing chemistries, bioinformatics tools, and miniaturized platforms are reducing cost per genome and expanding accessibility.
  • Whole genome sequencing (WGS), targeted gene panels, and whole exome sequencing (WES) are widely deployed in both research and clinical workflows.
  • Integration of AI in data interpretation and the use of cloud-based analysis platforms are simplifying NGS workflows and enabling real-time genomics.
  • Demand is rising across emerging economies, driven by government-backed genomics initiatives, biobank expansion, and local sequencing infrastructure development.
  • Non-invasive prenatal testing (NIPT), liquid biopsy, and microbiome profiling are among the fastest-growing NGS applications.
  • Key players include Illumina, Thermo Fisher Scientific, BGI Genomics, Agilent Technologies, and Pacific Biosciences.
  • North America dominates the market due to extensive adoption in clinical genomics, while Asia-Pacific is witnessing the fastest growth.
  • Data privacy, reimbursement challenges, and regulatory harmonization remain critical factors influencing clinical adoption.

Market Overview

The Next Generation Sequencing (NGS) market represents a transformative shift in genetic and molecular biology analysis, offering massively parallel sequencing at unparalleled speed, accuracy, and cost-effectiveness. NGS enables rapid sequencing of entire genomes, transcriptomes, or targeted panels, making it indispensable in areas such as oncology, genetic disease diagnostics, agricultural genomics, and drug discovery.

NGS platforms such as Illumina’s sequencing by synthesis (SBS), Oxford Nanopore’s real-time long-read systems, and PacBio’s SMRT sequencing are being integrated into clinical laboratories, academic institutions, biotech companies, and pharmaceutical R&D pipelines. The flexibility of NGS—ranging from single-cell resolution to metagenomic analysis—makes it suitable for applications across human health, environmental science, and synthetic biology.

As precision medicine gains momentum globally, NGS serves as the backbone for identifying disease-causing mutations, tailoring therapeutics, and monitoring treatment efficacy. Lower sequencing costs, improved informatics platforms, and regulatory support are collectively accelerating its clinical and commercial integration.

Next Generation Sequencing (NGS) Market Size and Forecast

The global NGS market was valued at USD 12.3 billion in 2024 and is projected to reach USD 33.8 billion by 2031, expanding at a CAGR of 15.4% during the forecast period.

This robust growth is attributed to increased use of NGS in clinical settings, particularly in oncology and hereditary disease diagnostics, as well as expanded applications in agriculture, forensics, and microbial genomics. The market is also benefiting from the proliferation of direct-to-consumer (DTC) genetic testing services and the global expansion of national genome programs in countries like the UK, China, Saudi Arabia, and Australia.

The widespread integration of cloud-based bioinformatics tools, combined with the emergence of real-time and portable sequencers, is driving deeper market penetration, especially in point-of-care and decentralized testing models.

Future Outlook

The future of the NGS market lies in automation, real-time sequencing, and AI-driven interpretation. Sequencing is expected to become a routine component of clinical diagnostics and disease management across oncology, cardiology, neurology, and infectious diseases. Portable sequencers and microfluidic systems will support field-based testing in remote and resource-limited settings.

Continued evolution of long-read technologies will address current limitations in structural variant detection, repeat regions, and epigenomic profiling. Simultaneously, cloud genomics and federated data architectures will enable secure and scalable interpretation of massive sequencing datasets.

Liquid biopsy-based cancer screening, early diagnosis of neurodegenerative diseases, and fetal genome sequencing will push the boundaries of NGS beyond research and into personalized, preventive healthcare models.

Next Generation Sequencing (NGS) Market Trends

  • Clinical Expansion of NGS
    The increasing adoption of NGS in routine clinical diagnostics is reshaping healthcare delivery. From identifying hereditary cancer syndromes to guiding immunotherapy decisions in oncology, NGS is becoming a standard diagnostic tool. Turnaround time improvements and cost reductions are making it viable for hospitals and smaller labs.
  • Rise of Long-Read and Real-Time Sequencing
    Long-read sequencing technologies from PacBio and Oxford Nanopore offer higher accuracy in detecting structural variants and repeat expansions. These methods also support native RNA sequencing and epigenetic analysis, unlocking new dimensions in transcriptomics and functional genomics.
  • NGS in Infectious Disease Surveillance
    NGS played a crucial role during the COVID-19 pandemic and continues to be used for pathogen surveillance and antimicrobial resistance monitoring. Global health bodies are integrating NGS into early outbreak detection and genomic epidemiology programs to manage future pandemics more effectively.
  • Integration of AI and Machine Learning
    AI-driven tools are streamlining the interpretation of complex NGS datasets. Algorithms are now being trained to identify clinically significant variants, detect novel mutations, and assist in disease classification. This is reducing interpretation time and improving accuracy in clinical reporting.
  • Decentralization and Miniaturization of Sequencers
    Portable, low-cost NGS platforms are enabling sequencing at the point of care, in the field, or at small clinics. These devices are transforming diagnostic workflows in resource-limited regions and supporting real-time disease tracking in agriculture and biosecurity sectors.

Market Growth Drivers

  • Demand for Precision Medicine
    The push for personalized therapies based on individual genetic profiles is fueling the integration of NGS in oncology, cardiology, and rare disease diagnostics. NGS enables clinicians to identify actionable mutations, guide targeted treatments, and improve patient outcomes.
  • Falling Sequencing Costs
    The cost of sequencing a human genome has dropped from USD 100 million in 2001 to less than USD 500 in 2024. This drastic cost reduction is enabling large-scale genomics initiatives, routine clinical testing, and affordable consumer genomic services.
  • Government Genomics Initiatives
    National programs like the UK’s 100,000 Genomes Project and China’s Precision Medicine Initiative are creating infrastructure, funding, and demand for sequencing. These programs are accelerating technology adoption in public health, research, and drug development sectors.
  • Growing Demand for Non-Invasive Testing
    Applications like NIPT, liquid biopsies, and cell-free DNA testing are gaining popularity due to their safety, accuracy, and early diagnostic value. NGS enables sensitive detection of low-frequency variants from trace nucleic acids in blood or saliva, supporting broad use in preventive medicine.
  • Expansion of Agricultural and Microbial Genomics
    NGS is being widely adopted in agriculture for crop improvement, soil microbiome analysis, and pathogen detection. In microbiology, it supports food safety, fermentation monitoring, and the study of antibiotic resistance genes across ecosystems.

Challenges in the Market

  • Data Storage and Interpretation Complexity
    NGS generates terabytes of data per run, posing challenges in storage, transmission, and analysis. Managing these datasets requires sophisticated infrastructure, skilled personnel, and secure, scalable cloud environments to support effective interpretation.
  • Regulatory and Reimbursement Uncertainty
    Clinical adoption is often slowed by inconsistent regulatory frameworks and lack of reimbursement policies across different regions. Diagnostic labs face hurdles in gaining regulatory approval for NGS-based tests and in securing insurance coverage for patients.
  • High Capital Investment and Operational Costs
    Setting up NGS infrastructure involves significant investment in sequencers, sample preparation units, and bioinformatics tools. Additionally, recurring costs such as reagents, maintenance, and skilled workforce create operational burdens for small and mid-sized labs.
  • Data Privacy and Ethical Concerns
    The sensitive nature of genomic data raises privacy issues and ethical debates around consent, data sharing, and incidental findings. Regulatory compliance with data protection laws like GDPR and HIPAA is essential, especially in clinical and consumer applications.
  • Bioinformatics Talent Gap
    The shortage of trained bioinformaticians and genomic analysts limits the ability of organizations to fully harness the potential of NGS. Developing user-friendly, automated analysis tools remains a priority to bridge this skill gap.

Next Generation Sequencing (NGS) Market Segmentation

By Technology

  • Sequencing by Synthesis (SBS)
  • Nanopore Sequencing
  • Single-Molecule Real-Time (SMRT) Sequencing
  • Ion Semiconductor Sequencing
  • Others

By Product & Services

  • Instruments
  • Reagents & Consumables
  • Software & Services

By Application

  • Oncology
  • Genetic Disease Diagnostics
  • Reproductive Health (NIPT, Carrier Screening)
  • Infectious Disease Surveillance
  • Agriculture & Animal Genomics
  • Metagenomics and Microbiome Studies

By End-user

  • Hospitals & Diagnostic Labs
  • Academic & Research Institutions
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Government & Public Health Agencies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Leading Players

  • Illumina Inc.
  • Thermo Fisher Scientific Inc.
  • BGI Genomics Co., Ltd.
  • Agilent Technologies Inc.
  • Pacific Biosciences of California, Inc.
  • Oxford Nanopore Technologies Ltd.
  • QIAGEN N.V.
  • F. Hoffmann-La Roche AG
  • Genewiz (A Brooks Company)
  • PerkinElmer Inc.

Recent Developments

  • Illumina Inc. launched NovaSeq X series with enhanced speed and AI-powered analysis tools, offering whole genome sequencing at scale with lower cost.
  • Thermo Fisher Scientific expanded its Ion Torrent platform for oncology testing, enabling targeted sequencing panels for clinical laboratories.
  • Oxford Nanopore Technologies released Q20+ chemistry for more accurate real-time sequencing, enabling direct RNA and epigenetic profiling.
  • BGI Genomics partnered with international hospitals for joint development of whole-genome based cancer diagnostics and pharmacogenomics solutions.
  • Pacific Biosciences introduced Revio system featuring long-read, high-throughput capabilities tailored for large genome studies and rare variant detection.
Sl. no.Topic
1Market Segmentation
2Scope of the report
3Research Methodology
4Executive summary
5Key Predictions of Next Generation Sequencing (NGS) Market
6Avg B2B price of Next Generation Sequencing (NGS) Market
7Major Drivers For Next Generation Sequencing (NGS) Market
8Global Next Generation Sequencing (NGS) Market Production Footprint - 2024
9Technology Developments In Next Generation Sequencing (NGS) Market
10New Product Development In Next Generation Sequencing (NGS) Market
11Research focus areas on new Wireless Infrastructure
12Key Trends in the Next Generation Sequencing (NGS) Market
13Major changes expected in Next Generation Sequencing (NGS) Market
14Incentives by the government for Next Generation Sequencing (NGS) Market
15Private investments and their impact on Next Generation Sequencing (NGS) Market
16Market Size, Dynamics And Forecast, By Type, 2025-2031
17Market Size, Dynamics And Forecast, By Output, 2025-2031
18Market Size, Dynamics And Forecast, By End User, 2025-2031
19Competitive Landscape Of Next Generation Sequencing (NGS) Market
20Mergers and Acquisitions
21Competitive Landscape
22Growth strategy of leading players
23Market share of vendors, 2024
24Company Profiles
25Unmet needs and opportunity for new suppliers
26Conclusion